Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Rituximab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Rituximab as a study intervention. Browse Rituximab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
663
Shown on this page
12
Local indexed summaries
663
Local recruiting
102
The trial list below is retrieved from the live ClinicalTrials.gov search API for Rituximab. Results on this page are currently sorted by Recently updated.

Filter and sort this therapy

These controls apply only within Rituximab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 1–12 of 663 matching trials for Rituximab.
Indexed local directory records.

Top conditions

Lymphoma 144 Chronic Lymphocytic Leukemia 41 Leukemia 40 Mantle Cell Lymphoma 36 Recurrent Mantle Cell Lymphoma 31 Follicular Lymphoma 30

Top sponsors

M.D. Anderson Cancer Center 78 National Cancer Institute (NCI) 52 Memorial Sloan Kettering Cancer Center 24 Hoffmann-La Roche 20 Alliance for Clinical Trials in Oncology 18 Mayo Clinic 17

Top locations

New York, New York 169 Houston, Texas 159 Chicago, Illinois 115 Boston, Massachusetts 114 Seattle, Washington 102 Columbus, Ohio 86

Indexed official records

Open in full search
Recruiting Phase 3 Interventional

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT07104032
View directory record Official record
Conditions
Relapsed/Refractory Primary Central Nervous System Lymphoma
Interventions
Rituximab, Temozolomide, Tirabrutinib
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Scottsdale, Arizona • Fullerton, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 12:56 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Bendamustine, Cyclophosphamide, Doxorubicin, Golcadomide, Lenalidomide, Prednisone/Prednisolone, Rituximab, Vincristine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 25 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 11:43 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

NCT06045247
View directory record Official record
Conditions
Large B-cell Lymphoma
Interventions
Cyclophosphamide, Epcoritamab, Prednisone, Rituximab, Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 12:52 AM EDT
Recruiting Phase 2 Interventional

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCT04840602
View directory record Official record
Conditions
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, Venetoclax, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
126
States / cities
Tucson, Arizona • Coral Gables, Florida • Coral Springs, Florida + 92 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

NCT02877303
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 12:54 AM EDT
Recruiting Phase 1 Interventional

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NCT07226843
View directory record Official record
Conditions
Follicular Lymphoma, Lymphoma, Diffuse Large B-Cell, Lymphoma, Non-Hodgkin's
Interventions
LY4584180, Rituximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 12:52 AM EDT
Recruiting Phase 3 Interventional

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Bendamustine, Cyclophosphamide, Doxorubicin, Odronextamab, Prednisone/prednisolone, Rituximab, Vincristine
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 10:46 AM EDT
Recruiting Phase 2 Interventional

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

NCT05645718
View directory record Official record
Conditions
Leukemia
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Inotuzumab ozogamicin, Mercaptopurine, Methotrexate, Pegfilgrastim, Prednisone, Rituximab, Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 10:46 AM EDT
Recruiting Phase 1 Interventional

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

NCT04318678
View directory record Official record
Conditions
AML/MDS, B-ALL, BPDCN, T-ALL
Interventions
CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, Rituximab
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 10:46 AM EDT
Recruiting Phase 2 Interventional

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855
View directory record Official record
Conditions
Membranous Nephropathy, Nephrotic Syndrome
Interventions
Belimumab, Placebo for Belimumab, Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 7:27 PM EDT
Recruiting Phase 3 Interventional

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851
View directory record Official record
Conditions
CLL, Leukemia, Chronic Lymphocytic, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic, SLL, Small-Cell Lymphoma
Interventions
Nemtabrutinib, Rituximab, Venetoclax
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
6
States / cities
Springdale, Arkansas • Long Beach, California • Pembroke Pines, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 20, 2026, 12:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
BMS-986353, Cyclophosphamide, Fludarabine, Nintedanib, Rituximab, Tocilizumab
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
16
States / cities
Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 20, 2026, 2:50 AM EDT

About this Rituximab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Rituximab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Rituximab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Rituximab.